Compare Johnson & Johnson (JNJ) vs Consumer Staples Select Sector SPDR Fund (XLP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Consumer Staples Select Sector SPDR Fund — how do they compare? Johnson & Johnson trades at $261.2 (market cap $618.09B), while Consumer Staples Select Sector SPDR Fund trades at $83.43 (market cap $13.50B). The key difference: Johnson & Johnson is far larger — about 45.8× Consumer Staples Select Sector SPDR Fund's market cap, and Johnson & Johnson pays a 2.09% dividend while Consumer Staples Select Sector SPDR Fund pays none. Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and Consumer Staples Select Sector SPDR Fund for 72 Days on average.
| JNJ | XLP | |
|---|---|---|
Market Cap | $618.09B | $13.50B |
Volume | 6,050,983 | 14,599,953 |
Sector | Health | — |
52-Week High | $278.43 | $90.00 |
52-Week Low | $186.00 | $75.61 |
Typical Hold Time | 129 Days | 72 Days |
Enterprise Value | $646.37B | — |
Dividend Yield | 2.09% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $259.62, up 0.45% with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with 21.48% net margin and 25.74% ROE, though valuation ratios appear elevated with P/E at 29.75. Recent news highlights growth in the Innovative Medicine segment and positive analyst coverage with 52.5% buy ratings.
JNJ offers stable dividend income and pharmaceutical innovation upside, but faces patent cliff risks and increasing debt-to-asset ratio (24.06% in 2025). Analyst consensus target of $286.53 suggests 10% upside potential, though technical resistance at $260 may limit near-term gains.
XLP (Consumer Staples Select Sector SPDR ETF) trades at $83.41, up 2.09% with bullish technical signals from moving averages and oscillators. The ETF shows strong relative performance, gaining 6.6% year-to-date while consumer discretionary stocks declined. Analyst sentiment is unanimously positive with 100% buy ratings, supported by the fund's low 0.08% expense ratio and defensive positioning during market volatility.
The outlook remains favorable given XLP's defensive characteristics amid economic uncertainty, though rising interest rates pose a headwind. The ETF's focus on household staples provides stability, with dividend income adding to total return potential. Key risks include inflation pressures and consumer spending shifts toward value-oriented options.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Consumer Staples Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies that have been identified as Consumer Staples companies by the GICS®. It is non-diversified.
Read more on XLP →
